Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.

2.

Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators.

N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.

3.

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Moyer VA; U.S. Preventive Services Task Force.

Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.

PMID:
22801674
4.

Mortality results from a randomized prostate-cancer screening trial.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18. Erratum in: N Engl J Med. 2009 Apr 23;360(17):1797.

5.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.

PMID:
21642681
6.

New data on prostate-cancer mortality after PSA screening.

Miller AB.

N Engl J Med. 2012 Mar 15;366(11):1047-8. doi: 10.1056/NEJMe1200185. No abstract available.

PMID:
22417259
7.

Screening for prostate cancer: the current evidence and guidelines controversy.

Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R.

Can J Urol. 2011 Oct;18(5):5875-83. Review.

8.

Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.

Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H, Loblaw DA, Roth B, Williams J, Nam RK.

J Clin Oncol. 2012 Aug 20;30(24):3020-5. doi: 10.1200/JCO.2012.43.3441. Epub 2012 Jul 16.

9.

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.

Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K.

Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7. Review.

PMID:
21984740
10.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Nov 2;306(17):1865-73. doi: 10.1001/jama.2011.1591. Epub 2011 Oct 26.

PMID:
22031728
11.

Lycopene, Tomato Products, and Prostate Cancer Incidence: A Review and Reassessment in the PSA Screening Era.

Wei MY, Giovannucci EL.

J Oncol. 2012;2012:271063. doi: 10.1155/2012/271063. Epub 2012 May 28.

12.

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. Epub 2010 Jul 2.

13.

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology.

Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.

PMID:
21056534
14.

Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials.

Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P.

BMJ. 2010 Sep 14;341:c4543. doi: 10.1136/bmj.c4543. Review.

15.

Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening.

Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL.

PLoS One. 2012;7(4):e34414. doi: 10.1371/journal.pone.0034414. Epub 2012 Apr 11.

16.

Screening and early diagnosis of prostate cancer: an update.

Lumen N, Fonteyne V, De Meerleer G, De Visschere P, Ost P, Oosterlinck W, Villeirs G.

Acta Clin Belg. 2012 Jul-Aug;67(4):270-5. Review.

PMID:
23019802
17.

Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL; Urologic Diseases in America Project.

BJU Int. 2012 Oct;110(7):1050-9. doi: 10.1111/j.1464-410X.2011.10867.x. Epub 2012 Mar 19.

18.

Clinical decisions. Screening for prostate cancer.

D'Amico AV, Smith MR.

N Engl J Med. 2012 Aug 16;367(7):e11. doi: 10.1056/NEJMclde1209426. No abstract available.

19.

Clinical practice. Screening for prostate cancer.

Hoffman RM.

N Engl J Med. 2011 Nov 24;365(21):2013-9. doi: 10.1056/NEJMcp1103642. Epub 2011 Oct 26. Review. No abstract available.

20.

PSA-based screening for prostate cancer. Too many adverse effects.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):215-7. Review.

PMID:
23016259

Supplemental Content

Support Center